Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses

Background There is a lack of synthesis of literature to determine hepatitis B vaccine (HepB) strategies for hepatitis B virus (HBV) supported by quality evidence. We aimed to explore the efficacy and safety of HepB strategies among people with different characteristics.Research design and methods P...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiamin Qiu, Shiwen Zhang, Yonghui Feng, Xin Su, Jun Cai, Shiyun Chen, Jiazi Liu, Shiqi Huang, Haokun Huang, Sui Zhu, Huiyan Wen, Jiaxin Li, Haoyu Yan, Zhiquan Diao, Xiaofeng Liang, Fangfang Zeng
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Expert Review of Vaccines
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2023.2289566
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846141400687575040
author Jiamin Qiu
Shiwen Zhang
Yonghui Feng
Xin Su
Jun Cai
Shiyun Chen
Jiazi Liu
Shiqi Huang
Haokun Huang
Sui Zhu
Huiyan Wen
Jiaxin Li
Haoyu Yan
Zhiquan Diao
Xiaofeng Liang
Fangfang Zeng
author_facet Jiamin Qiu
Shiwen Zhang
Yonghui Feng
Xin Su
Jun Cai
Shiyun Chen
Jiazi Liu
Shiqi Huang
Haokun Huang
Sui Zhu
Huiyan Wen
Jiaxin Li
Haoyu Yan
Zhiquan Diao
Xiaofeng Liang
Fangfang Zeng
author_sort Jiamin Qiu
collection DOAJ
description Background There is a lack of synthesis of literature to determine hepatitis B vaccine (HepB) strategies for hepatitis B virus (HBV) supported by quality evidence. We aimed to explore the efficacy and safety of HepB strategies among people with different characteristics.Research design and methods PubMed, Cochrane Library, Embase, and Web of Science were searched for meta-analyses comparing the efficacy and safety of HepB up to July 2023.Results Twenty-one meta-analyses comparing 83 associations were included, with 16 high quality, 4 moderate, and 1 low quality assessed by AMSTAR 2. Highly suggestive evidence supports HepB booster and HepB with 1018 adjuvant (HBsAg-1018) for improved seroprotection, and targeted and universal HepB vaccination reduced HBV infection Suggestive evidence indicated that targeted vaccination decreased the rate of hepatitis B surface antibody positivity and booster doses increased seroprotection in people aged 10–20. Weak evidence suggests potential local/systemic reaction risk with nucleotide analogs or HBsAg-1018. Convincing evidence shows HLA-DPB1*04:01 and DPB1*04:02 increased, while DPB1*05:01 decreased, hepatitis B antibody response. Obesity may reduce HepB seroprotection, as highly suggested.Conclusion Targeted vaccination could effectively reduce HBV infection, and adjuvant and booster vaccinations enhance seroprotection without significant reaction. Factors such as obesity and genetic polymorphisms may affect the efficacy.
format Article
id doaj-art-371e49de9d5243d2b74d4bf8d323001a
institution Kabale University
issn 1476-0584
1744-8395
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Expert Review of Vaccines
spelling doaj-art-371e49de9d5243d2b74d4bf8d323001a2024-12-04T09:49:48ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-01231698110.1080/14760584.2023.2289566Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analysesJiamin Qiu0Shiwen Zhang1Yonghui Feng2Xin Su3Jun Cai4Shiyun Chen5Jiazi Liu6Shiqi Huang7Haokun Huang8Sui Zhu9Huiyan Wen10Jiaxin Li11Haoyu Yan12Zhiquan Diao13Xiaofeng Liang14Fangfang Zeng15Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, PR ChinaBackground There is a lack of synthesis of literature to determine hepatitis B vaccine (HepB) strategies for hepatitis B virus (HBV) supported by quality evidence. We aimed to explore the efficacy and safety of HepB strategies among people with different characteristics.Research design and methods PubMed, Cochrane Library, Embase, and Web of Science were searched for meta-analyses comparing the efficacy and safety of HepB up to July 2023.Results Twenty-one meta-analyses comparing 83 associations were included, with 16 high quality, 4 moderate, and 1 low quality assessed by AMSTAR 2. Highly suggestive evidence supports HepB booster and HepB with 1018 adjuvant (HBsAg-1018) for improved seroprotection, and targeted and universal HepB vaccination reduced HBV infection Suggestive evidence indicated that targeted vaccination decreased the rate of hepatitis B surface antibody positivity and booster doses increased seroprotection in people aged 10–20. Weak evidence suggests potential local/systemic reaction risk with nucleotide analogs or HBsAg-1018. Convincing evidence shows HLA-DPB1*04:01 and DPB1*04:02 increased, while DPB1*05:01 decreased, hepatitis B antibody response. Obesity may reduce HepB seroprotection, as highly suggested.Conclusion Targeted vaccination could effectively reduce HBV infection, and adjuvant and booster vaccinations enhance seroprotection without significant reaction. Factors such as obesity and genetic polymorphisms may affect the efficacy.https://www.tandfonline.com/doi/10.1080/14760584.2023.2289566Hepatitis B vaccinesefficiencysafetysystematic reviewmeta-analysis
spellingShingle Jiamin Qiu
Shiwen Zhang
Yonghui Feng
Xin Su
Jun Cai
Shiyun Chen
Jiazi Liu
Shiqi Huang
Haokun Huang
Sui Zhu
Huiyan Wen
Jiaxin Li
Haoyu Yan
Zhiquan Diao
Xiaofeng Liang
Fangfang Zeng
Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses
Expert Review of Vaccines
Hepatitis B vaccines
efficiency
safety
systematic review
meta-analysis
title Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses
title_full Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses
title_fullStr Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses
title_full_unstemmed Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses
title_short Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses
title_sort efficacy and safety of hepatitis b vaccine an umbrella review of meta analyses
topic Hepatitis B vaccines
efficiency
safety
systematic review
meta-analysis
url https://www.tandfonline.com/doi/10.1080/14760584.2023.2289566
work_keys_str_mv AT jiaminqiu efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT shiwenzhang efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT yonghuifeng efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT xinsu efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT juncai efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT shiyunchen efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT jiaziliu efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT shiqihuang efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT haokunhuang efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT suizhu efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT huiyanwen efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT jiaxinli efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT haoyuyan efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT zhiquandiao efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT xiaofengliang efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses
AT fangfangzeng efficacyandsafetyofhepatitisbvaccineanumbrellareviewofmetaanalyses